The role
0401* Programme leadership & platform: overall responsibility for the Cellular Therapies platform and leadership of the SCT Division, in close collaboration with the relevant clinical disciplines, including Hematology, Oncology, Immunology and Metabolic Medicine, to further develop autologous/allogeneic SCT and cellular therapies (CAR-T, gene and other advanced cell therapies).
02* JACIE programme leadership: direction of the JACIE-/EBMT-accredited centre across all domains (CIC 334, Clinics, Collection, Processing, IES) under QM guidelines. GMP laboratory in cooperation with the GMP laboratory management.
03* Strategy & networking: securing the national centre function and international integration (EBMT, SIOPE, IBFM, ITCC, ESID, NCCR Children & Cancer).
04* Collaboration: cooperation, including interdisciplinary processes, with Hematology, Oncology, lmmunology, Rheumatology, Neurology and Metabolism, as well as with referring centres, registries, specialist organisations and authorities (Federal Office of Public Health, Swissmedic).
05* Research: laboratory space at the Children's Research Centre is available for a research group. Excellent re-search environment.
06* Innovation & translation: joint clinical & JACIE lead for GMP lab. Introduction of new procedures, e.g. graft processing, immunomodulation, ex-vivo/ in-vivo cell engineering, alternative conditioning regimens and cellular therapies for malignant and non-malignant indications (immunotherapies, gene therapies). Clinical trials & IITs: participation in international clinical trials (EBMT, JACIE, etc.) and development of own investigator-initiated trials (IITs).
07* Leadership & Talent: fostering an interdisciplinary and interprofessional team of physicians (FTE 5.6), scientists (FTE 5.2) and nursing staff (FTE 15). Support of early-career researchers.
